The DOI matches its Crossref record.
Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer
Abstract
Cyclin dependent kinases 4 and 6 (CDK4 and CDK6) and cyclin dependent kinase 2 (CDK2) act in a coordinated fashion to phosphorylate and repress RB protein, effectively driving cell proliferation via E2F activation. Currently, CDK4/6 inhibitors in combination with endocrine therapy are considered the standard of care for the treatment of hormone-receptor (HR)-positive/HER2-negative breast cancer, but unfortunately most patients with metastatic disease ultimately progress. High CCNE1 expression is considered one of the underlying mechanisms of resistance to CDK4/6-inhibition, and other adaptations to chronic CDK4/6-inhibition that increase reliance on the CDK2 pathway to sustain RB-E2F signaling are also thought to reduce CDK4/6 inhibitor effectiveness. Based on this, we reason that, targeting CDK2 in conjunction with CDK4/6 inhibition can provide more sustained and durable responses in this difficult-to-treat patient population. To identify molecular glue degraders (MGDs) that selectively target CDK2, we used our MGD discovery engine QuEENTM. Through this platform that encompasses biochemical and cellular assays as well as in silico modelling, we identified and further optimized molecules that induce CRBN engagement to drive selective CDK2 degradation. Unlike CDK2 inhibitors, our CDK2 MGDs spare other proteins such as closely related CDKs and, attesting to their superior selectivity, inhibit cell proliferation in an RB-dependent manner. Furthermore, these MGDs induce robust downstream pathway suppression, as evidenced by downmodulation of RB phosphorylation and E2F-driven gene expression. When dosed orally in in vivo models of HR-positive/HER2-negative breast cancer, these compounds drive deep tumor regression in combination with CDK4/6 inhibitor or triple combination with endocrine therapy (fulvestrant), resulting in enhanced downstream pathway suppression compared to CDK4/6 inhibitor alone. Owing to their superior selectivity, we expect that a CDK2 MGDs will avoid dose-limiting toxicities associated with less selective CDK2 inhibitors. Hence, CDK2 MGDs provide novel means to target an inadequately drugged target, offering a unique angle for populations in desperate need of treatment options. Citation Format: Sofia Gkountela, William Tahaney, Vasiliki Vafeiadou, Christelle Bianda, Liam Cheeseman, Ambika Singh, Anna Diesslin, Martin Schillo, Sophia Nguyen, Luca Moccia, Christopher King, Yimao Liu, Chao Quan, Bradley DeMarco, Laura Schwander, Vaik Strande, Jessica Alers, Rajiv Narayan, Dave Peck, Sarah Pessa, Samuel Gilberto, John Castle, Filip Janku, Sharon Townson, Markus Warmuth, Magnus Walter, Beatrice Ranieri, Ralph Tiedt, Nina Ilic Widlund. Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB422.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent public disclosures by biotech companies have reported additional non G-loop targets, including CCNE1 (50), ARNT (51), CDK2 (52), ALK (53)”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [52]
Citations
Cites
Still being checked.
Cited by
Rudolph, J., Hoeflich, K. P., & Dar, A. C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01411-9 · Cited by 13
Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues
Ojeda, S., Wang, M., Baek, K., Bourgeois, W., Sommerschield, A., Yue, H., Metivier, R. J., Karagiannis, P., Levitz, T. S., Xiong, Y., et al. (2026) · Science · doi:10.1126/science.aef5391 · Cited by 5
Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy
Rubin, S. M., Sage, J., & Skotheim, J. M. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-0916 · Cited by 6
Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
Ma, L., Wang, N., Zhu, J., Wu, L., He, S., & Zhang, B. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.020 · Cited by 8
Selective CDK2 Degradation via Noncanonical Recruitment
Pei, Y., Lin, W., Li, X., Meng, Y., Yin, Y., Pan, B., Zhou, L., Cao, L., Cang, Y., Jiang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01264 · Cited by 2
Metadata
- Authors
- Gkountela, S., Tahaney, W., Vafeiadou, V., Bianda, C., Cheeseman, L., Singh, A., Diesslin, A., Schillo, M., Nguyen, S., Moccia, L., King, C., Liu, Y., Quan, C., DeMarco, B., Schwander, L., Strande, V., Alers, J., Narayan, R., Peck, D., Pessa, S., Gilberto, S., Castle, J., Janku, F., Townson, S., Warmuth, M., Walter, M., Ranieri, B., Tiedt, R., & Widlund, N. I.
- Affiliations
- 1Monte Rosa Therapeutics AG, Basel, Switzerland;
- Massachusetts Institute for a New Commonwealth (US)
- 2Monte Rosa Therapeutics, Inc., Boston, MA.
- ORCID
- Venue
- Cancer Research
- Published
- 2025-04-25
- Volume
- 85
- Issue
- 8_Supplement_2
- Pages
- LB422-LB422
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4409821144
- Cited by
- 7
- References
- 0
- Citations by year
- 2026: 7
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK2, molecular glues, hormone receptor-positive HER2-negative breast cancer, CDK4/6 inhibitors, cereblon, cyclin E1, drug resistance, fulvestrant, endocrine therapy, selective protein degradation, oral anticancer drugs, metastatic breast cancer, cell proliferation inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer. https://app.cochat.ai/papers/10.1158/1538-7445.am2025-lb422
- The paper
- Gkountela, S., Tahaney, W., Vafeiadou, V., Bianda, C., Cheeseman, L., Singh, A., Diesslin, A., Schillo, M., Nguyen, S., Moccia, L., King, C., Liu, Y., Quan, C., DeMarco, B., Schwander, L., Strande, V., Alers, J., Narayan, R., Peck, D., . . . Widlund, N. I. (2025). Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer. Cancer Research. https://doi.org/10.1158/1538-7445.am2025-lb422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.